Psychedelics Management Updates: Two Top Companies Appoint New CEOs, Here's What We Know

Two companies in the psychedelics space have chosen new chief executive officers: COMPASS Pathways (NASDAQ: CMPS) has chosen Kabir Nath, and Small Pharma will be now led by George Tziras.

Compass Pathways Adds Kabir Nath On Board

Nath will effectively become chief executive officer as of August 1, 2022, bringing decades of experience in the healthcare industry to his new role, most recently serving as senior managing director of global pharmaceuticals at Otsuka Pharmaceutical Co., Ltd. (OTC: OTSKF) and previously as president and CEO of Otsuka’s North America Pharmaceutical Business. Prior to Otsuka, Nath held various leadership positions at Bristol Myers Squibb (NYSE: BMY), a global biopharma company. 

In his new role, Nath is expected to continue advancing patient access to evidence-based innovative care models combining pharmacological, psychological and digital solutions, while Goldsmith will continue in his role as Chairman helping shape public-private partnerships, advocacy and efforts to improve outcomes in mental health.

On the decision, COMPASS’ current CEO and chairman George Goldsmith expressed confidently: “As we enter the next stage of development, Kabir brings a …

Full story available on Benzinga.com

Psychedelics Management Updates: Two Top Companies Appoint New CEOs, Here's What We Know on Benzinga